Clinical Trial

Immune Responses Induced by a N. Meningitidis Vaccine

Study Description

Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine

The purpose of this study is to test whether the group B meningitis vaccine (brand name Bexseroa"c) induces immune responses against the bacteria that causes gonorrhea. Participants: Approximately 15 Individuals who are 18-25 years of age that are not pregnant, HIV negative, have no history of congenital immunologic disorder, and are not taking immune suppressive medications will be enrolled on this study at a single site, UNC-CH (University of North Carolina at Chapel Hill). Procedures (methods): Participants will receive two-doses of an FDA-approved vaccine that provides protection from N. meningitidis infection according to the recommended dosing schedule. The first vaccine dose will be given to participants at the entry visit and the second vaccine dose will be given to participants at the week 5 visit. The participants will provide samples of blood as well as mucosal surface derived samples (urine and/or swabs) at four separate visits (entry, week 5, week 6, and week 7).

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Biological - Meningococcal Group B Vaccine

All participants will receive the 4CMenB vaccine, 0.5 mL, at entry (Day 0) and at week 5.

Additional Information

Official Study Title

IGHID (Institute for Global Health and Infectious Diseases) 11911 - Cross-reactive N. Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine

Clinical Trial ID

NCT04094883

ParticipAid ID

dwpLMe